SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Joshi Manher

(Last)

(First)

(Middle)

C/O ATARA BIOTHERAPEUTICS, INC.

2380 CONEJO SPECTRUM STREET, SUITE 200

(Street)

THOUSAND OAKS

91320

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2023

3. Issuer Name and Ticker or Trading Symbol
Atara Biotherapeutics, Inc. [ ATRA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	190,546⁽¹⁾⁽²⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	08/01/2020	08/31/2023	Common Stock	75,000	$19.85	D
Employee Stock Option (Right to Buy)	02/06/2022	02/05/2025	Common Stock	35,000	$35.8	D
Employee Stock Option (Right to Buy)	02/06/2023	02/05/2029	Common Stock	30,350	$38.47	D
Employee Stock Option (Right to Buy)	06/01/2023	02/28/2030	Common Stock	54,640	$12.15	D
Employee Stock Option (Right to Buy)	⁽³⁾	02/28/2030	Common Stock	12,610	$12.15	D
Employee Stock Option (Right to Buy)	06/01/2023	02/28/2031	Common Stock	32,022	$17.105	D
Employee Stock Option (Right to Buy)	⁽⁴⁾	02/28/2031	Common Stock	24,907	$17.105	D
Employee Stock Option (Right to Buy)	06/01/2023	02/29/2032	Common Stock	31,359	$10.21	D
Employee Stock Option (Right to Buy)	⁽⁵⁾	02/29/2032	Common Stock	68,991	$10.21	D
Employee Stock Option (Right to Buy)	06/01/2023	02/28/2033	Common Stock	18,468	$3.91	D
Employee Stock Option (Right to Buy)	⁽⁵⁾	02/28/2033	Common Stock	203,159	$3.91	D

Explanation of Responses:

1. Includes an aggregate 185,436 restricted stock units ("RSUs"), which are comprised of: (i) 6,312 RSUs that vest as to 1/3rd of shares on August 15, 2023 and each of the next two (2) Quarterly Vesting Dates (as defined herein); (ii) 5,625 RSUs that vest as to 1/3rd of shares on August 15, 2023 and each of the next two (2) Quarterly Vesting Dates; (iii) 16,502 RSUs that vest as to 1/7th of shares on August 15, 2023 and each of the next six (6) Quarterly Vesting Dates; (iv) 36,704 RSUs that vest as to 1/11th of shares on August 15, 2023 and each of the next ten (10) Quarterly Vesting Dates; (v) 30,000 RSUs that vest as to 1/2nd of shares on November 15, 2023 and 1/2nd on November 15, 2024; and (vi) 90,293 RSUs that vest as to 1/11th of shares on August 15, 2023 and each of the next ten (10) Quarterly Vesting Dates, each of which is subject to the reporting person's continuous service.

2. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the "Quarterly Vesting Date" shall be the first (1st) business day after such date.

3. 1/9th of shares subject to the stock option vest and become exercisable on July 1, 2023, and the remaining shares vest in equal monthly installments over the following eight (8) months, subject to the reporting person's continuous service.

4. 1/21st of shares subject to the stock option vest and become exercisable on July 1, 2023, and the remaining shares vest in equal monthly installments over the following twenty (20) months, subject to the reporting person's continuous service.

5. 1/33rd of shares subject to the stock option vest and become exercisable on July 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-two (32) months, subject to the reporting person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jeff Kiekhofer, Attorney-in-Fact for Manher Joshi	06/09/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.